Biotech Stocks New Highs: Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN), Celladon Corp (NASDAQ:CLDN), Kindred Biosciences (NASDAQ:KIN)



Fate Therapeutics, Inc. (NASDAQ:FATE) announced that it has enrolled the first patient in its phase II study (PUMA − P rohema in UM bilical cord blood transplant in A dults) on Prohema. Fate Therapeutics Inc. (NASDAQ:FATE) stock performance was 27.14% in last session and finished the day at $11.15. Traded volume was 295,227.00 shares in the last session and the average volume of the stock remained 34,881.00 shares. Fate Therapeutics Inc. (NASDAQ:FATE) insider ownership is 1.20%.

Synthetic Biologics, Inc. (NYSEMKT:SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced on 10 march that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA). Synthetic Biologics Inc. (NYSEMKT:SYN) rose 6.10% to $3.13 yesterday on volume of 3.62 million shares. The intra-day range of the stock was $2.98 – $3.20. Synthetic Biologics Inc. (NYSEMKT:SYN) has a market capitalization of 139.77 million.

Celladon Corp (NASDAQ:CLDN) on Mar. 4 announced it has completed enrollment and randomized 250 patients in the phase 2b trial titled “Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease,” known as CUPID 2, which is evaluating the efficacy and safety of MYDICAR (AAV1/SERCA2a) in patients with NYHA class III/IV symptoms of systolic heart failure. Celladon Corp (NASDAQ:CLDN)’s stock on March 14, 2014 reported a higher of 8.05% to the closing price of $15.84. Its fifty two weeks range is $7.45 – $15.95. The total market capitalization recorded 271.01 million. The overall volume in the last trading session was 144,182.00 shares. In its share capital, Celladon Corp (NASDAQ:CLDN) has 17.11 million outstanding shares.

Kindred Biosciences (NYSE:KIN) was downgraded by stock analysts at Roth Capital from a “buy” rating to a “neutral” rating in a report issued on Friday, TheFlyOnTheWall.com reports. They currently have a $25.00 price target on the stock, up from their previous price target of $20.00. Roth Capital’s price objective points to a potential upside of 2.46% from the company’s current price. On Friday, shares of Kindred Biosciences Inc. (NASDAQ:KIN) dropped -1.94% to close the day at $24.24. Company return on investment (ROI) is – and its monthly performance is recorded as 25.47%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone